Publications by authors named "L E Flanders"
Article Synopsis
- The study looked at how different treatments affect kidney tumors in patients with advanced kidney cancer.
- It found that a combination of immune therapy and a specific type of cancer drug worked best, reducing tumor size significantly in 50% of patients.
- The researchers suggest testing this treatment more to see if it can help more patients before surgery for kidney cancer.
The standard-of-care for muscle-invasive bladder cancer is radical surgery with neoadjuvant cisplatin-based chemotherapy. Despite curative intent from these interventions, relapse rates post-surgery remain high, with approximately 50% of patients developing local or distant recurrence within 2 years of surgery and a 5-year survival of only 50-60%. Identifying patients who are high risk for relapse post-surgery is a priority.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated cancer patients receiving systemic anti-cancer treatment (SACT) at Guy's Cancer Centre during the COVID-19 pandemic to guide future clinical practices.
- A total of 2120 patients received SACT in 2020, a 13% decrease compared to 2449 in 2019, with notable changes in treatment types and stages, including an increase in stage IV cases.
- Despite the pandemic's challenges, the findings indicate that SACT continued effectively with a low SARS-CoV2 infection rate of 2%, suggesting minimal impact on patient mortality for those with solid tumors.
Article Synopsis
- ICPi-AKI (immune checkpoint inhibitor-associated acute kidney injury) is a significant concern for cancer patients, occurring about 16 weeks after starting treatment and often linked to lower kidney function and certain medications.
- A study involving 429 patients found that about 64% experienced recovery of kidney function after receiving corticosteroids, especially when treatment started early.
- Rechallenging patients with ICPis after kidney injury showed a 16.5% recurrence rate of kidney issues, but there was no significant difference in survival compared to those who were not rechallenged.